-CEO Speaking At Evercore
Guggenheim Maintains Buy on Life Time Group Hldgs, Raises Price Target to $21
Guggenheim analyst John Heinbockel maintains Life Time Group Hldgs (NYSE:LTH) with a Buy and raises the price target from $17 to $21.
Related Posts
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
On Friday, Pfizer Inc (NYSE: PFE) revealed its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial. On Monday, Moderna (NASDAQ: MRNA) and Merck & Co (NYSE:
UBS Maintains Buy on Capri Holdings, Lowers Price Target to $65
UBS analyst Jay Sole maintains Capri Holdings (NYSE:CPRI) with a Buy and lowers the price target from $91 to $65.
Ensysce Biosciences Announces Initiation Of Second Human Abuse Potential Study, Being Conducted By Dr. Vince Clinical Research
~ Oral Opioid Abuse Being Explored for PF614 ~
~ Data From Trial Supports Abuse Deterrent Labeling, Designed to Measure the Potential for Drug Liking ~
SAN DIEGO, CA / ACCESSWIRE / September 22, 2022 / Ensysce